Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies. - Luke JJ; Gelmon K; Siu LL; Moreno V; Desai J; Gomez-Roca CA; Carlino MS; Pachynski RK; Cosman R; Chu QS; Damian S; Curigliano G; et al. (Clinical cancer research : an official journal of the American Association for Cancer Research, 2025)